Evidence map›Paper›PMID 27225496›Full record

ReviewPharmaceutical research2016

Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.

Amanda K Pearce, Adrian V Fuchs, Nicholas L Fletcher, Kristofer J Thurecht

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 28 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Amanda K PearceCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology and the ARC Centre of Excellence in Convergent BioNano Science and Technology, The University of Queensland, Building 57, St Lucia, QLD, 4072, Australia.
Adrian V FuchsCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology and the ARC Centre of Excellence in Convergent BioNano Science and Technology, The University of Queensland, Building 57, St Lucia, QLD, 4072, Australia.
Nicholas L FletcherCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology and the ARC Centre of Excellence in Convergent BioNano Science and Technology, The University of Queensland, Building 57, St Lucia, QLD, 4072, Australia.
Kristofer J ThurechtCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology and the ARC Centre of Excellence in Convergent BioNano Science and Technology, The University of Queensland, Building 57, St Lucia, QLD, 4072, Australia. k.thurecht@uq.edu.au.
University of Queensland · AUARC Centre of Excellence in Advanced Molecular Imaging · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis manuscript utilised in vivo multispectral imaging to demonstrate the efficacy of two different nanomedicine formulations for targeting prostate cancer.

methodsPegylated hyperbranched polymers were labelled with fluorescent markers and targeting ligands against two different prostate cancer markers; prostate specific membrane antigen (PSMA) and the protein kinase, EphrinA2 receptor (EphA2). The PSMA targeted nanomedicine utilised a small molecule glutamate urea inhibitor of the protein, while the EphA2 targeted nanomedicine was conjugated to a single-chain variable fragment based on the antibody 4B3 that has shown high affinity to the receptor.

resultsHyperbranched polymers were synthesised bearing the different targeting ligands. In the case of the EphA2-targeting nanomedicine, significant in vitro uptake was observed in PC3 prostate cancer cells that overexpress the receptor, while low uptake was observed in LNCaP cells (that have minimal expression of this receptor). Conversely, the PSMA-targeted nanomedicine showed high uptake in LNCaP cells, with only minor uptake in the PC3 cells. In a dual-tumour xenograft mouse model, the nanomedicines showed high uptake in tumours in which the receptor was overexpressed, with only minimal non-specific accumulation in the low-expression tumours.

conclusionsThis work highlighted the importance of clearly defining the target of interest in next-generation nanomedicines, and suggests that dual-targeting in such nanomedicines may be a means to achieve greater efficacy.

Indexed as

AnimalsAntigens, SurfaceAntineoplastic AgentsBiomarkers, TumorDrug Delivery SystemsDrug Evaluation, PreclinicalGlutamate Carboxypeptidase IIHumansLigandsMaleNanomedicineProstatic NeoplasmsReceptor, EphA2Antigens, SurfaceAntineoplastic AgentsBiomarkers, TumorFOLH1 protein, humanGlutamate Carboxypeptidase IILigandsReceptor, EphA2antibodyfluorescence imagingmolecular imagingnanomedicinenanotherapeutics

Identifiers

PMID27225496
OpenAlexW2397969975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.